Implications of the START study data — questions and answers

11 June 2015

UNAIDS welcomes additional evidence released in May 2015 that early initiation of antiretroviral therapy has a positive effect on the health and well-being of people living with HIV. The United States National Institutes of Health-funded international randomized clinical trial START (Strategic Timing of Antiretroviral Treatment) has found compelling evidence that the benefits of starting antiretroviral therapy as soon as someone is diagnosed outweigh the risks of delaying until their CD4 count has fallen to 350 cells/mm3.